Biogen Idec ‘s ( BIIB ) shares were down 2.74% after the company announced that the US Food and Drug Administration (FDA) has extended its review period for the company’s oral
Original post:
BIIB’s BG-12 Review Period Extended – Analyst Blog
Biogen Idec ‘s ( BIIB ) shares were down 2.74% after the company announced that the US Food and Drug Administration (FDA) has extended its review period for the company’s oral
Original post:
BIIB’s BG-12 Review Period Extended – Analyst Blog